Maquet Cardiovascular, LLC Sustainability Profile
Maquet Cardiovascular, LLC, a prominent player in the medical device industry, is headquartered in the United States. Founded in 1838, the company has established itself as a leader in cardiovascular solutions, focusing on innovative technologies for cardiac surgery and critical care. With a strong presence in North America and Europe, Maquet Cardiovascular is renowned for its advanced products, including heart-lung machines and surgical instruments, which are designed to enhance patient outcomes and streamline surgical procedures. The company’s commitment to quality and innovation has earned it a significant market position, with notable achievements in developing cutting-edge technologies that improve surgical efficiency. Maquet Cardiovascular continues to set industry standards, making it a trusted partner for healthcare professionals worldwide.
DitchCarbon Score
How does Maquet Cardiovascular, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Machinery and Equipment industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Maquet Cardiovascular, LLC's score of 87 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Maquet Cardiovascular, LLC, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Getinge AB (publ), which influences its climate commitments and initiatives. As part of its corporate family relationship, Maquet Cardiovascular inherits climate-related targets and initiatives from Getinge AB. This includes commitments to the Science Based Targets initiative (SBTi) and other sustainability frameworks, although specific reduction targets for Maquet Cardiovascular are not detailed. The absence of direct emissions data suggests that Maquet Cardiovascular is in the process of developing its own climate strategy, potentially aligning with the broader goals set by Getinge AB. The company is expected to contribute to the overarching sustainability efforts of its parent organisation, which may include initiatives aimed at reducing Scope 1, 2, and 3 emissions. In summary, while specific emissions data for Maquet Cardiovascular is not available, the company is positioned within a framework of climate commitments inherited from Getinge AB, indicating a commitment to sustainability and carbon reduction in line with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 6,351,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 22,687,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 000,000 |
| Scope 3 | - | - | - | 0,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Maquet Cardiovascular, LLC's Industry?
How Carbon Intensive is Maquet Cardiovascular, LLC's Location?
Maquet Cardiovascular, LLC's Scope 3 Categories Breakdown
Maquet Cardiovascular, LLC's Scope 3 emissions, which decreased by 8% last year and increased significantly since 2019, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 49% of Scope 3 emissions.
Top Scope 3 Categories
Maquet Cardiovascular, LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Maquet Cardiovascular, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
